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VaccineInformation about influenza vaccine effectiveness (IVE) is important for vaccine strain selection and
immunization policy decisions. The test-negative design (TND) case-control study is commonly used to
obtain IVE estimates. However, the definition of the control patients may influence IVE estimates. We
have conducted a TND study using the Dutch Sentinel Practices of NIVEL Primary Care Database which
includes data from patients who consulted the General Practitioner (GP) for an episode of acute
influenza-like illness (ILI) or acute respiratory infection (ARI) with known influenza vaccination status.
Cases were patients tested positive for influenza virus. Controls were grouped into those who tested
(1) negative for influenza virus (all influenza negative), (2) negative for influenza virus, but positive for
respiratory syncytial virus, rhinovirus or enterovirus (non-influenza virus positive), and (3) negative
for these four viruses (pan-negative). We estimated the IVE over all epidemic seasons from 2003/2004
through 2013/2014, pooled IVE for influenza vaccine partial/full matched and mismatched seasons and
the individual seasons using generalized linear mixed-effect and multiple logistic regression models.
The overall IVE adjusted for age, GP ILI/ARI diagnosis, chronic disease and respiratory allergy was 35%
(95% CI: 15–48), 64% (95% CI: 49–75) and 21% (95% CI: 1 to 39) for all influenza negative, non-
influenza virus positive and pan-negative controls, respectively. In both the main and subgroup analyses
IVE estimates were the highest using non-influenza virus positive controls, likely due to limiting inclu-
sion of controls without laboratory-confirmation of a virus causing the respiratory disease.
 2017 Elsevier Ltd. All rights reserved.1. Introduction
The most effective way to prevent influenza virus infection and
(severe) illness is by vaccination [1]. However, the composition of
the influenza vaccine should be reconsidered annually, and even-
tually updated, due to amino acid substitutions causing antigenic
drifts of the hemagglutinin and neuraminidase virus surface pro-
teins which occurs continually over time to escape neutralization
by the immune response [2,3]. Despite the yearly update, the abil-ity of the vaccine to prevent influenza virus infection in the general
population during an influenza season (vaccine effectiveness [VE])
varies each year [4]. Hence, VE information is important for immu-
nization policy decision makers, e.g. to decide which type of vac-
cine should be used (i.e. inactivated or live attenuated virus, with
or without adjuvant) and who should be immunized (e.g. health
care workers, children, elderly) [5]. However, it is not possible to
determine the VE before an influenza season. Therefore, retrospec-
tive studies using observational data are performed to estimate the
VE annually [4,6].
The test-negative design (TND) case-control study is a com-
monly used study design to estimate influenza VE (IVE). In this
study design, patients seeking medical care for influenza-like ill-
ness (ILI) are tested for influenza virus infection [7]. The IVE is
2832 E. van Doorn et al. / Vaccine 35 (2017) 2831–2839determined by comparing the prevalence of influenza vaccination
between ILI patients who tested positive for influenza [cases] and
those who tested negative for influenza [controls] [7,8]. As both
cases and controls are selected from patients seeking medical care
for ILI, the study design is assumed to minimize confounding by
health care-seeking behavior or functional status compared to
other types of observational studies [9–11]. Moreover, laboratory
tests are used to define the influenza outcome which, compared
to other study designs using non-specific influenza outcomes
(e.g. ILI symptoms), reduces misclassification bias [9–11].
Several studies have shown that the definition of the control
group in TND studies may influence the estimates of the IVE
[12–16]. Three types of control groups have been used in TND
studies: (1) all ILI patients tested negative for influenza virus infec-
tion (all influenza negative), (2) ILI patients tested negative for
influenza virus but positive for another respiratory virus (non-
influenza virus positive), and (3) ILI patients tested negative for
both influenza virus and other respiratory viruses (pan-negative)
[11–18]. Although all influenza negative controls are commonly
used, in several studies non-influenza virus positive controls have
been used arguing that if another respiratory virus than influenza
virus could be detected in the control group, the presence of mis-
classification is highly unlikely, as there is a confirmed infectious
cause of ILI in both cases and controls. This is based on the fact that
the same laboratory tests for influenza virus are used for both cases
and controls [13,15,16]. On the other hand, other investigators
argued that the presence of a non-influenza respiratory virus infec-
tion could be partly explained by the association between influ-
enza vaccination and the increased risk of another respiratory
virus infection due to a temporary nonspecific immune response
[10–12,18,19]. Consequently, the definition of the second control
group could lead to selection bias and thereby an overestimation
of IVE since the risk of ILI symptoms caused by another pathogen
would be higher in the vaccinated patients than in unvaccinated
patients, resulting in a higher proportion of vaccinated individuals
in the control group [11,12,14,17,18]. As a consequence, several
studies have used pan-negative controls.
The aim of the present study is to estimate the IVE over ten
influenza epidemic seasons in The Netherlands (from 2003/2004
to 2013/2014) using the three most commonly applied definitions
of TND control groups and evaluate the differences among the IVE
estimates.2. Methods
2.1. Study database
We used data from the Sentinel Practices of NIVEL Primary Care
Database [20,21]. Sampling of patients with ILI or another acute
respiratory infection (ARI) for laboratory diagnostics started in
1992. Since 2003 participating general practitioners (GPs) are
asked to take nose and throat swabs from two ILI patients each
week. Since 2005/2006 with the additional instruction to sample
preferably one patient less than 10 years of age. If no ILI patients
are encountered, the GP is asked to swab patients with another
ARI instead [22]. The official standard definition of ILI was used
in the GP offices to diagnose a patient with ILI, namely an acute
onset of symptoms (full development of typical symptoms in
4 days) including a rectal temperature of at least 38 C and at
least one respiratory or systemic symptom (i.e. cough, nasal cat-
arrh, sore throat, frontal headache, retrosternal pain, myalgia)
[21]. ARI is defined as an acute respiratory illness other than ILI,
such as acute sinusitis or pneumonia, and with at least one of
the following symptoms; coughing, rhinorrhea or sore throat
[23]. Both ILI and ARI patients were included in this study to max-imize the power. Patient information is registered on the sample
form, e.g. personal information (gender, age), date of symptoms
onset and swabbing, use of antiviral medication and underlying
medical conditions. The surveillance study has been registered in
the Personal Data Protection Act Register of the Dutch Personal
Data Protection Commission [No. RIVM/EPI-043]. No further ethi-
cal approval was needed since only anonymized data was used
for the current study.
2.2. Laboratory testing
Collected samples from all swabbed subjects were sent to the
National Institute for Public Health and the Environment (RIVM)
for laboratory tests for a number of pathogens. These pathogens
were identified using virus isolation and/or reverse transcription
polymerase chain reaction (RT-PCR). RT-PCR changed over time
from conventional block-based to real-time format with necessary
adjustments in primer and probe design. Laboratory tests for the
respiratory viruses influenza virus, respiratory syncytial viruses
(RSV), rhinovirus (RV) and enterovirus (EV) were performed
throughout the study period from 2003 to 2014. Laboratory tests
for other pathogens differed per season: the identification of
parainfluenza virus (PIV) type 1–4, coronavirus (CoV) (229E,
OC43 and NL63) and metapneumovirus (hMPV) stopped after the
2007/2008 influenza season and adenovirus (ADV) was tested only
from 2005 until the 2007/2008 season. We used information on
these other pathogens for sensitivity analyses only.
2.3. Selection of cases and controls
For each influenza season from 2003/2004 through 2013/2014
patients were selected when they were swabbed between week
48 and week 14 of the following year. Patients were excluded if
(1) the vaccination status was unknown, (2) time between symp-
toms onset and swabbing was more than seven days, (3) a patient
had received antiviral medication within the two weeks prior to
the GP visit, (4) the date of swabbing was before the first of Decem-
ber of each season to make sure vaccination was given 14 days
before symptoms onset, or (5) data was missing on other variables
(i.e. gender, age, ILI/ARI diagnosis, underlying chronic disease and
respiratory allergy) [7,24]. Patients swabbed in the season
2009/2010 were excluded since this was an atypical (pandemic)
influenza season. Eligible swabbed patients who tested positive
for influenza virus A(H1N1), A(H1N1)pdm09, A(H3N2) or B were
regarded as cases. Controls were defined as those patients tested
(1) negative for influenza virus (all influenza negative) (2) negative
for influenza virus, but positive for RSV, RV or EV (non-influenza
virus positive), and (3) negative for these four respiratory viruses
(pan-negative). We included RSV, RV and EV since only these
viruses were tested throughout the whole study period.
2.4. Statistical analysis
Chi-square tests were used to test for significant differences in
proportions of categorical covariates, and T-tests for differences
in mean age between cases and control groups. A P-value <0.05
was considered statistically significant.
IVE was calculated by IVE = (1  OR)  100% with influenza vac-
cine status as the exposure [7]. The unadjusted and adjusted IVE
for potential confounders were estimated, i.e. age, ILI/ARI diagno-
sis, respiratory allergy, underlying chronic disease (e.g. asthma,
chronic obstructive pulmonary diseases, diabetes mellitus and car-
diovascular diseases), influenza season and level of vaccine match.
Variables that were associated with the outcome (changed the
OR > 5%) were retained in the final generalized linear mixed-
effect model (GLMM) or multiple logistic regression model. When
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tive values, the IVE was considered significant [25].
The GLMM in which influenza seasons are modelled as a ran-
dom effect was used to estimate the IVE over all seasons and by
seasons categorized by level of vaccine match [26]. Vaccine match
status was categorized as (partial) match or mismatch based on the
circulating influenza viruses and seasonal influenza vaccines used
which information was extracted from data published by the
Dutch National Influenza Center [26–37]. The multiple logistic
regression model was used to assess the IVEs for the individual
seasons. Statistical analyses were conducted using SAS software
(version 9.4) and R (version 3.2.0) [38].2.4.1. Sensitivity analysis
We performed several sensitivity analysis. We estimated (1) the
overall IVE excluding seasons 2003/2004 and 2004/2005 since
those two seasons had a low number of subjects in the control
group, especially the non-influenza virus positive controls, (2)
the overall IVE including the pandemic season of 2009/2010 were
the vaccination status was based on receiving the seasonal influ-
enza vaccine only, (3) the overall IVE using the patients which
were swabbed within 4 days after symptom onset and (4) weTable 1
Characteristics of cases and the three different control groups: all influenza negative (Cont
group 3).
Cases (n = 1297) Controls (n = 2754)
Control group 1 (n = 2
Gender
Female 668 (51.5%) 1470 (53.4%)
Male 629 (48.5%) 1284 (46.6%)
P1 = 0.280
Age 0–83 (Mean: 31.8) 0–93 (Mean: 34.4)
0–4 years 115 (8.9%) 397 (14.4%)
5–14 years 242 (18.7%) 282 (10.2%)
15–59 years 816 (62.9%) 1637 (59.4%)
60 years 124 (9.5%) 438 (15.9%)
P1 < 0.001
Diagnosis
ARI 261 (20.0%) 1237 (44.9%)
ILI 1036 (80.0%) 1517 (55.1%)
P1 < 0.001
Time between symptom onset and swab date
<3 days 479 (36.9%) 950 (34.5%)
3–5 days 711 (54.8%) 1430 (51.9%)
6–7 days 107 (8.3%) 374 (13.6%)
P1 < 0.001
Any chronic disease 77 (5.9%) 286 (10.4%)
P1 < 0.001
Respiratory allergy 107 (8.2%) 221 (8.0%)
P1 = 0.855
Influenza vaccination 171 (13.2%) 579 (21.0%)
P1 < 0.001
Seasons
Matcha 442 (34.1%) 775 (28.1%)
Partially matchb 191 (14.7%) 491 (17.8%)
Mismatchc 664 (51.2%) 1488 (54.0%)
P1: Comparison cases versus controls. P2: Comparison Control group 2 versus Control gr
a Seasons: 2008–2009; 2010–2011.
b Seasons: 2005–2006; 2006–2007.
c Seasons: 2003–2004; 2004–2005; 2007–2008; 2011–2012; 2012–2013; 2013–2014calculated the IVE for the influenza seasons 2005/2006,
2006/2007 and 2007/2008 using laboratory test results of PIV virus
1–4, CoV, RSV, hMPV, RV, EV and ADV. Influenza virus negative
patients testing positive for at least one, or negative for all the
viruses were considered as non-influenza virus positive and pan-
negative controls, respectively. This sensitivity analysis was con-
ducted since the definition of the control groups is similar to pre-
viously conducted studies [12–16].3. Results
3.1. Subject Characteristics
GPs of the Dutch Sentinel Practices network swabbed a total of
11,199 patients from 2003 through 2014. From these, 4051 (36%)
fulfilled the in- and exclusion criteria for this study (Table 1). The
majority of subjects were excluded because they were swabbed
outside the influenza season (4153, 37%). Other subjects were
excluded since information on e.g. age, clinical diagnosis or influ-
enza vaccination was missing (928, 8%), the time between symp-
tom onset and swabbing was more than seven days (1444, 13%)
or they had received antiviral medication within two weeks priorrol group 1), non-influenza virus positive (Control group 2) and pan-negative (Control
754) Control group 2 (n = 676) Control group 3 (n = 2078)
339 (50.1%) 1131 (54.4%)
337 (49.9%) 947 (45.6%)
P1 = 0.600 P1 = 0.105
P2 = 0.058
0–93 (Mean: 27.0) 0–91 (Mean: 36.8)
213 (31.5%) 184 (8.9%)
78 (11.5%) 204 (9.8%)
291 (43.0%) 1346 (64.8%)
94 (13.9%) 344 (16.6%)
P1 < 0.001 P1 < 0.001
P2 < 0.001
335 (49.6%) 902 (43.4%)
341 (50.4%) 1176 (56.6%)
P1 < 0.001 P1 < 0.001
P2 = 0.006
263 (38.9%) 687 (33.1%)
335 (49.6%) 1095 (52.7%)
78 (11.5%) 296 (14,2%)
P1 = 0.011 P1 < 0.001
P2 = 0.044
65 (9.6%) 221 (10.6%)
P1 = 0.004 P1 < 0.001
P2 = 0.495
62 (9.2%) 159 (7.7%)
P1 = 0.542 P1 = 0.574
P2 = 0.237
142 (21.0%) 437 (21.0%)
P1 < 0.001 P1 < 0.001
P2 = 1.000
164 (24.3%) 611 (29.4%)
134 (19.8%) 357 (17.2%)
378 (55.9%) 1110 (53.4%)
oup 3.
.
2834 E. van Doorn et al. / Vaccine 35 (2017) 2831–2839to the GP visit (62, 1%). From the included subjects, a total of 1297
(32%) patients tested positive for influenza virus (cases) and 2754
(68%) tested negative for influenza virus. Among those patients
testing negative for influenza virus, 676 (25%) tested positive for
RSV, RV or EV (non-influenza virus positive) and 2078 (75%) tested
negative for these viruses (pan-negative). Statistical significant dif-
ferences in age, GP ILI/ARI diagnosis, presence of any chronic dis-
ease and influenza vaccination status were found between cases
and the different control groups. Compared to the control groups,
cases were younger, more likely to be diagnosed with ILI, and
had a lower proportion of any chronic disease and influenza vacci-
nation. In addition, there were statistically significant differences
in age and diagnosis when comparing the non-influenza virus pos-
itive and pan-negative controls; pan-negative controls were older
and were more likely to be diagnosed with ILI compared to non-
influenza virus positive controls (see Table 1).
3.2. Determination of confounding factors
When comparing the unadjusted IVE estimates with IVE esti-
mates adjusted for possible confounding factors, age, ILI/ARI diag-
nosis, chronic disease, respiratory allergy and the influenza season
changed the OR by more than 5%. Therefore, in the following para-
graphs only IVE estimates adjusted for these confounding factors
are shown (influenza season parameter not included in estimating
season-specific IVE).
3.3. Overall IVE estimate
The adjusted IVE estimate over all seasons was 35% (95% CI 15–
48) when using all influenza negative controls (Fig. 1). When using
non-influenza virus positive controls the IVE increased to 64% (95%
49–75) whereas the IVE decreased to 21% (95% CI 1 to 39) when
using the pan-negative controls.
3.4. (Mis)matched seasons
From 2003 to 2014, the vaccine strains and circulating viruses
(partially) matched in the seasons 2005/2006, 2006/2007,-20 -10 0 10
35 (15 - 48)
Overall  64 (49 - 75)
21 (-1 - 39)
39 (16 - 56)
(Partially) matched 62 (40 - 76)
30 (2 - 50)
31 (7 - 49)
Mismatched  66 (47 - 78)
14 (-18 - 37)
Control group 1 Control gro
Fig. 1. Adjusted1 influenza vaccine effectiveness (IVE) against laboratory-confirmed i
seasons2. Significant IVE indicated in bold. Control group 1 = all influenza negative contr
negative controls. 1Adjusted for age, ILI/ARI diagnosis, chronic disease, respiratory aller
2006–2007, 2008–2009 and 2010–2011. Mismatched seasons include all other seasons2008/2009 and 2010/2011 (Table 2) [27–37]. The pooled adjusted
IVE estimates for these (partially) matched seasons were 39% (95%
CI 16–56), 62% (95% CI 40–76) and 30% (95% CI 2–50) for all influ-
enza negative, non-influenza virus positive and pan-negative con-
trols, respectively (Fig. 1). The pooled adjusted IVE estimates for
the mismatched seasons were 31% (95% CI 7–49), 66% (95% CI
47–78) and 14% (95% CI 18 to 37) for Control group 1–3,
respectively.
3.5. IVE estimates individual influenza seasons
Adjusted IVE estimates for the different individual influenza
seasons varied from negative IVE estimates to 95% (Fig. 2). Signif-
icant IVE estimates were identified for the 2007/2008, 2010/2011
and 2012/2013 seasons irrespective of the control group used.
Except for season 2013/2014 when using all influenza negative,
no significant IVE estimates were identified for any of the other
seasons. In all seasons, with the exception of season 2005/2006,
the estimated adjusted IVE was the highest for non-influenza virus
positive controls, followed by all influenza negative and pan-
negative controls.
3.6. Sensitivity analysis
The results of the sensitivity analysis are summarized in Table 3.
The adjusted overall IVE estimates increased when excluding sea-
sons 2003/2004 and 2004/2005. The pooled overall IVE estimate
was 42% (95% CI 25–55), 66% (95% CI 51–76) and 30% (95% CI 8–
46) for all influenza negative, non-influenza virus positive and
pan-negative controls, respectively. When including the pandemic
season of 2009/2010 the adjusted IVE estimates are comparable
with the main analysis. On the other hand the adjusted IVE esti-
mates decreased when restricting to subjects which were swabbed
within 4 days after disease onset. For the sensitivity analysis using
the laboratory test results of PIV virus 1–4, CoV, RSV, hMPV, RV, EV
and ADV to define the cases and controls, 343 eligible patients
tested positive for influenza virus (cases) and 794 tested negative
(all influenza negative). Among those tested negative for influenza
virus 288 (36%) and 506 (64%) patients were included as non-20 30 40 50 60 70 80 90 10
0
IVE% (95% CI)
up 2 Control group 3
nfluenza in The Netherlands for all seasons combined and for the (mis)matched
ols; Control group 2 = non-influenza virus positive controls; Control group 3 = pan-
gy and influenza season. 2(Partially) matched seasons include seasons 2005–2006,
from the study period.
Table 2
Proportion of virus (sub)types and lineages (%) and vaccine mismatch per subtype/lineage based on virus isolates and specimens submitted to the National Influenza Center with a specimen collection date in week 40 of one year
through week 39 of the following year.
Influenza season
Virus (sub)type 2003/04 2004/05 2005/06 2006/07 2007/08 2008/09 2009/
2010
2010/11 2011/12 2012/13 2013/2014
Proportion of virus (sub) types (%)
A 99 80 64 99 49 92 100 60 90 69 94
A(H1N1)a 0 18 4 13 86 1 100 97 1 39 40
A(H3N2) 100 82 96 87 14 99 0 3 99 61 60
B 1 20 36 1 51 8 0 40 10 31 6
B Y Y Y/V Y Y V NA Y/V Y/V Y/V Y/V
B/Vic 91 95 12 6 24
B/Yam 9 5 88 94 76
Mismatch per subtype
A(H1N1) NA No No Yes Yes No Yesb No No No No
A(H3N2) Yes Yes No No No No NA No Yes Yes Yes
B/Vic NA NA Yes (Yam in
vaccine)
NA NA Yes (Yam in
vaccine)
NA No No NA NA




















Mismatch Mismatch Partially match Partially
match
Mismatch Match Mismatch Match Mismatch Mismatch Mismatch
V: B/Victoria/2/87-lineage; Y: B/Yamagata/16/88-lineage; NA: Not applicable.
Bold percentages indicate the predominant viruses per season. An influenza virus was considered as predominant when detected in a proportion of 60% among the total influenza virus detections in week 40 through week 39 of
the following year.
a 2003/2004 through 2008/2009 season former seasonal A(H1N1); 2009/2010 through 2013/2014 season A(H1N1)pdm09.
b Former seasonal A(H1N1) in the vaccine; A(H1N1)pdm09 monovalent vaccine was available to too late in season.
c The influenza vaccine was considered to be a match if at least one of the two following criteria was fulfilled: (1) all the vaccine components were antigenically similar to the circulating A subtypes (H1N1 or H1N1pdm09 and
H3N2) and B lineages (Victoria or Yamagata); (2) vaccine stain antigenically matched the predominant and one of the non-predominant circulating virus subtypes. The influenza vaccine was considered to partially matched if the


















-11 (-354 - 75)
03/04  -130 (-806 - 86)
-36 (-483 - 69)
-86 (-357 - 23)
04/05                           
-116 (-453 - 12)
25 (-67 - 67)
05/06     11 (-219 - 74)
30 (-60 - 70)
-1 (-138 - 59)
06/07     29 (-125 - 78)
-6 (-161 - 59)
82 (55 - 94)
07/08        95 (82 - 99)
77 (39 - 92)
-12 (-107 - 41)
08/09       40 (-63 - 77)
-25 (-136 - 35)
59 (26 - 78)
10/11        80 (53 - 92)
50 (5 - 74)
-30 (-232 - 53)
11/12     31 (-136 - 80)
-54 (-307 - 45)
69 (45 - 83)
12/13        90 (73 - 96)
57 (19 - 78)
61 (2 - 86)
13/14         64 (-1 - 88)
57 (-16 - 86)
0 25 50 75 10
0
IVE% (95% CI)
Control group 1 Control group 3Control group 2
Fig. 2. Adjusted1 influenza vaccine effectiveness (IVE) against laboratory-confirmed
influenza in The Netherlands for the individual seasons2. Significant IVE indicated in
bold. Control group 1 = all influenza negative controls; Control group 2 = non-
influenza virus positive controls; Control group 3 = pan-negative controls. 1Adjusted
for age, ILI/ARI diagnosis, chronic disease and respiratory allergy. 2VE could not be
estimated for the seasons 2003/2004 and 2004/2005 due to the small sample size.
Table 3
Adjusted vaccine effectiveness estimates against laboratory-confirmed influenza
sensitivity analysis.














swab  4 days




33 (15–47) 63 (48–74) 20 (3 to 37)
IVE using several laboratory test resultsc to define control group
Season 2005/2006 24 (69 to 67) 4 (155 to 63) 44 (38 to 78)
Season 2006/2007 8 (158 to 56) 39 (81 to 80) 30 (234 to 51)
Season 2007/2008 82 (55–94) 92 (78–98) 73 (28–91)
Control group 1 = all influenza negative controls; Control group 2 = non-influenza
virus positive controls; Control group 3 = pan-negative controls.
Significant IVE indicated in bold.
a Adjusted for age, ILI/ARI diagnosis, chronic disease and respiratory allergy, and
for the overall estimates for influenza season.
b Vaccination status based on seasonal vaccine only.
c PIV virus 1 to 4, CoV, RSV, hMPV, RV, EV and ADV.
2836 E. van Doorn et al. / Vaccine 35 (2017) 2831–2839influenza virus positive and pan-negative controls respectively
(Table 4). The adjusted IVE estimates for the 2005/2006,
2006/2007 and 2007/2008 seasons with the different controlgroups varied from negative estimates to 92% (Table 3). The
adjusted IVE was only statistically significant for the 2007/2008
season when using the different control groups. For all sensitivity
analysis the IVE estimate was the highest when using non-
influenza virus positive controls, followed by all influenza negative
controls and pan-negative controls.
4. Discussion
In general, the point IVE estimates varied for the different def-
initions of control patients and were generally, but not in each
season, the highest when using non-influenza virus positive con-
trols, followed by respectively all influenza negative controls and
pan-negative controls which is consistent with other studies
[12,13,15,18].
Similar differences in IVE estimates were found in a study per-
formed in Portugal, in which the IVE was estimated for the mis-
matched 2012/2013 influenza season among ILI patients which
were tested on RSV, PIV, hMPV, RV and ADV to define the control
group patients [12,39]. On the other hand, an American study
which estimated the IVE over six influenza seasons (2004/2005
through 2009/2010) among children and adults aged 50 years
and older found only minor differences in the IVE estimates when
using the different control groups based on the detection of the
same viruses as the Portugal study and enterovirus [14]. However,
other studies performed in Australia which estimated the IVE in
children for the matched influenza season of 2008/2009 and
2008–2012 seasons using all influenza negative and non-
influenza positive controls, found the highest IVE estimates when
using non-influenza positive controls [13,15]. The IVE estimate
for (partial) matched seasons using non-influenza positive controls
in our study is higher than the IVE estimate in a Dutch randomized
controlled trial (RCT) conducted with patients aged 60 years and
older (50% (95% CI: 35–61)) in the matched season of 1991–1992
[40,41]. Moreover, the IVE estimate for mismatched seasons in
our study is also higher than the IVE estimate found in a Cochrane
review of RCTs with healthy subjects aged 18–65 years when using
non-influenza positive controls (55% (95% CI: 41–66)) [42].
The variation in the IVE estimates using different control groups
can be explained by selection bias or misclassification bias
[11,12,17]. In order to reduce selection bias, several studies sug-
gested including non-influenza ILI patients tested negative for
other respiratory viruses as controls (pan-negative controls). This
suggestion is based on the assumption that influenza vaccination
may increase the risk of a non-influenza respiratory virus infection
by a temporary nonspecific immunity (viral interference), resulting
in a higher proportion of vaccinated individuals in the control
group [11–14,17,18]. In our study we found no indication that
influenza vaccination might have increased the risk of non-
influenza respiratory virus infection in vaccinated patients. We
observed no difference in the vaccination coverage between the
non-influenza positive controls and pan-negative controls (cover-
age in both groups 21.0% (P = 1.00)) [13]. Others have indicated
that if a temporary nonspecific immunity is present, this is a short
lasting response (around two weeks). Therefore, it is unlikely that
this response influences the risk of other non-influenza respiratory
viruses throughout the full study period since we have only
included swabbed patients who received the vaccine at least
14 days before symptom onset [14,19,43]. Although, this explana-
tion is only true when we assume individuals are susceptible to
influenza virus infection only at the beginning of the study period
and timing of infections is not taken into account [44].
It should especially be questioned which population patients is
represented by pan-negative controls since these are ILI/ARI
patients tested negative for the evaluated respiratory viruses, i.e.
ILI/ARI patients without an infection of one of the tested
Table 4
Characteristics of cases and three different control groups sensitivity analysis: all influenza negative (Control group 1), non-influenza virus positive (Control group 2) and pan-
negative (Control group 3).
Cases (n = 343) Controls (n = 794)
Control group 1 (n = 794) Control group 2 (n = 288) Control group 3 (n = 506)
Gender
Female 180 (52.5%) 410 (51.6%) 145 (50.3%) 265 (52.4%)
Male 163 (47.5%) 384 (48.4%) 143 (49.7%) 241 (47.6%)
P1 = 0.845 P1 = 0.650 P1 = 1.00
P2 = 0.635
Age 0–83 (Mean: 31.4) 0–93 (Mean: 34.3) 0–93 (Mean: 30.8) 0–89 (Mean: 36.3)
0–4 years 30 (8.7%) 101 (12.7%) 64 (22.2%) 37 (7.3%)
5–14 years 65 (19.0%) 95 (12.0%) 40 (13.9%) 55 (10.9%)
15–59 years 218 (63.6%) 480 (60.5%) 138 (47.9%) 342 (67.6%)
60 years 30 (8.7%) 118 (14.9%) 46 (16.0%) 72 (14.2%)
P1 = 0.028 P1 = 0.765 P1 < 0.001
P2 = 0.001
Diagnosis
ARI 73 (21.3%) 320 (40.3%) 126 (43.8%) 194 (38.3%)
ILI 270 (78.7%) 474 (59.7%) 162 (56.2%) 312 (61.7%)
P1 < 0.001 P1 < 0.001 P1 < 0.001
P2 < 0.001
Time between symptom onset and swab date
<3 days 147 (42.9%) 304 (38.3%) 112 (38.9%) 192 (37.9%)
3–5 days 177 (51.6%) 412 (51.9%) 158 (54.9%) 254 (50.2%)
6–7 days 19 (5.5%) 78 (9.8%) 18 (6.2%) 60 (11.9%)
P1 = 0.040 P1 = 0.592 P1 = 0.006
P2 = 0.035
Any chronic disease 21 (6.1%) 94 (11.8%) 42 (14.6%) 52 (10.3%)
P1 = 0.005 P1 < 0.001 P1 = 0.046
P2 < 0.001
Respiratory allergy 16 (4.7%) 69 (8.7%) 31 (10.8%) 38 (7.5%)
P1 = 0.025 P1 = 0.006 P1 = 0.128
P2 = 0.152
Influenza vaccination 31 (9.0%) 151 (19.0%) 62 (21.5%) 89 (17.6%)
P1 < 0.001 P1 < 0.001 P1 < 0.001
P2 = 0.206
Influenza season
2005–2006 103 (30.0%) 221 (27.8%) 87 (30.2%) 134 (26.5%)
2006–2007 88 (25.7%) 265 (33.4%) 101 (35.1%) 164 (32.4%)
2007–2008 152 (44.3%) 308 (38.8%) 100 (34.7%) 208 (41.1%)
P1: Comparison cases versus controls. P2: Comparison Control group 2 versus Control group 3.
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health care-seeking behavior, and therefore include a higher pro-
portion of ILI/ARI not caused by infection, since patients in this con-
trol groupwere older and the prevalence of any chronic disease was
higher compared to the cases and other control groups. Also the
delay in swabbing might play a role since the time between symp-
tom onset and swabbing influences the sensitivity of laboratory
tests [45,46]. If the time between swabbing and symptoms onset
is greater, the sensitivity of influenza A and B viruses RT-PCR detec-
tion decreases, e.g. from 88% for 4 days till 70% for 7 days delay [46].
In our study, 14.2% of the pan-negative patients were swabbed 6–
7 days after symptom onset compared to 13.6% and 11.5% of all
influenza negative and non-influenza virus positive controls.
The sensitivity of the laboratory tests is also important for the
assumption of including patients tested negative for influenza
virus but positive for another respiratory virus as control group
(non-influenza positive controls). The inclusion of this control
group is based on the assumption that laboratory tests are ade-
quate for both cases and controls, thereby eliminating false-
negative controls and misclassification bias. However, in the cur-
rent study different laboratory techniques have been used to detect
an infection with one of the tested pathogens. RT-PCR was used
throughout the whole study period to detect influenza virus, RSV,
RV and EV infection. However, due to innovations in these tech-
niques over the study period, the sensitivity of the assays hasincreased a little. This might have reduced misclassification in later
seasons. Furthermore, in season 2004/2005 only virus isolation
was used for the detection of RV and EV, which also was the
method used to detect PIV virus infections. Virus isolation has a
lower sensitivity than RT-PCR. Due to this sensitivity gap misclas-
sification of patients can still not be ruled out absolutely [46–48].
Our sensitivity analysis excluding the seasons 2003/2004 and
2004/2005 for the overall estimate showed higher IVE estimates
compared to the primary analysis, especially when using all influ-
enza negative and pan-negative controls. No significant difference
between the IVE estimates could be observed when using the dif-
ferent control groups, the confidence intervals overlapped more
than in the primary analysis. When including the pandemic season
the overall estimates were almost identical to the estimates from
the primary analysis. However, when restricting to patients who
were swabbed within 4 days after disease onset the IVE estimates
decreased, especially when using non-influenza positive controls.
Also the sensitivity analysis which used several extra respiratory
pathogens to define the control groups, showed slightly different
IVE estimates compared to the primary analysis which included
three respiratory viruses for the definition of control groups. How-
ever, no general trend (increase or decrease of the IVE) could be
observed when comparing the IVE estimates of the primary and
sensitivity analyses which may be explained by the relative infre-
quent occurrence of these infections in primary care.
2838 E. van Doorn et al. / Vaccine 35 (2017) 2831–2839We were able to analyze the IVE estimates over several seasons
among the Dutch general practice population using the TND study
with different control groups, however our study has several limi-
tations. Firstly, a certain level of misclassification might be present
in the non-influenza virus positive controls and pan-negative con-
trols due to the differences in sensitivity of the laboratory tests
used for the detection of other pathogens, especially for those
detected by RT-PCR and those detected by virus isolation [49,50].
Secondly, due to the limited number of eligible patients both
patients diagnosed by the GP with ILI and ARI were included in this
study to maximize the power. However, there may be differences
in health care-seeking behavior of these two patient groups, which
could have resulted in misclassification bias. Moreover, patients in
the Sentinel Practices of NIVEL Primary Care Database network are
not a systematic sample of ILI/ARI patients in the population since
most persons with ILI/ARI will not visit their GP and from those
who visit the GP, the GP did not have a strict instruction about
which patients to sample (e.g. first patients in the week). In addi-
tion, subjects who have been hospitalized with an influenza virus
infection through the first aid are not covered by the NIVEL Pri-
mary Care database, since those subjects are swabbed in the hospi-
tal. Despite including both ILI and ARI patients, the number of
eligible patients was limited which resulted in wide confidence
intervals and only few statistically significant IVE estimates.
Finally, we did do not have information on how the vaccination
status per individual patient was exactly collected and this might
have resulted in misclassification bias. However, since all inhabi-
tants in the Netherlands are registered at one GP office, we can
assume that if the GP has vaccinated the patient that the GP takes
this information from the registry data of the patient.
5. Conclusion
Our study shows differences in the IVE estimates when using
three different control groups which are in line with other studies.
Pan-negative controls seems less valid because a high proportion
of patients in this group likely consult the GP because of non-
infectious causes of ILI or ARI symptoms. When using non-
influenza positive controls, the IVE estimates are more consistent
with previous effectiveness studies and clinical trial data, likely
due to limiting controls without an infectious cause of respiratory
disease; all controls have a laboratory confirmed infection explain-
ing ILI and ARI symptoms. Nevertheless, when using non-influenza
positive controls a higher IVE estimate was found in the primary
analysis for mismatched seasons compared to matched seasons
which is not as expected, but based on the sensitivity analysis
seemed to be caused by the mismatched seasons. Future studies
using the TND design should take into account the potential impact
of defined control group as well as vaccine match status. Further
studies on the study design are needed to confirm our findings
and to give a more clear statement about the differences observed
between the control groups. Future research on the study design
should include more patients to be able to detect statistical signif-
icant IVE estimates, especially since adjusting for confounding is
needed. This possibly can be done by expanding the GP network,
increasing the number of patients a GP has to swab or by pooling
data from several countries [51–53]. In addition, it is recom-
mended for future studies to use if feasible, standardized equal-
sensitive tests for pathogen detection throughout the whole study
period to minimize misclassification bias, although innovations in
diagnostic tests increasing the sensitivity should not be ignored.
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